Thomas Pangia

Director, New Business Assessment at Lupin Pharmaceuticals

Speaker

Thomas Pangia is Director of New Business Assessment at Lupin Pharmaceuticals, where he helps evaluate and support the company's global specialty rare disease portfolio. He brings more than a decade of experience spanning scientific research, corporate strategy, commercial product planning, and business development. Thomas earned his PhD in Chemistry from Johns Hopkins University and began his career in strategy consulting at L.E.K. Consulting, advising life sciences companies on corporate strategy and rare disease commercial opportunities. He later led rare disease diagnostic development and partnership initiatives at Metabolon before joining Lupin, where he focuses on new product planning and strategic assessment of differentiated therapies for patients with rare diseases.